Following a full submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Insulin degludec/liraglutide (Xultophy®) is recommended as an option for restricted use within NHS Wales. Insulin degludec/liraglutide (Xultophy®) is licensed for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to other oral medicinal products for the treatment of diabetes. Insulin degludec/liraglutide (Xultophy®) is restricted for use in combination with oral glucose-lowering medicinal products when these combined with basal insulin do not provide adequate glycaemic control. Insulin degludec/liraglutide (Xultophy®) is not recommended for use within NHS Wales outside of this subpopulation. |
|||
|
|||
Medicine details |
|||
| Medicine name | insulin degludec / liraglutide (Xultophy®) | ||
| Formulation | 100 units/ml / 3.6 mg/ml solution for injection | ||
| Reference number | 2544 | ||
| Indication | Treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to other oral medicinal products for the treatment of diabetes. |
||
| Company | Novo Nordisk Ltd | ||
| BNF chapter | Endocrine system | ||
| Submission type | Full | ||
| Status | Recommended with restrictions | ||
| Advice number | 2715 | ||
| NMG meeting date | 09/09/2015 | ||
| AWMSG meeting date | 21/10/2015 | ||
| Ratification by Welsh Government | 17/11/2015 | ||
| Date of issue | 18/11/2015 | ||
| Date of last review | September 2020 | ||